Viral hepatitis E: Clinical manifestations, treatment, and prevention☆

Qiumin Luo; Jia Chen; Yeqiong Zhang; Wenxiong Xu; Ying Liu; Chan Xie; Liang Peng

doi:10.1016/j.livres.2024.01.001

Liver Research ›› 2024, Vol. 8 ›› Issue (1) :11 -21. DOI: 10.1016/j.livres.2024.01.001

Review article

research-article

Viral hepatitis E: Clinical manifestations, treatment, and prevention^☆

Qiumin Luo ^a^,^b
, Jia Chen ^a^,^b
, Yeqiong Zhang ^a^,^b
, Wenxiong Xu ^a^,^b
, Ying Liu ^a^,^b
, Chan Xie ^a^,^b^,^*
, Liang Peng ^a^,^b^,^*

Author information +

History +

PDF (1057KB)

Abstract

Hepatitis E is a globally distributed infection that varies in seroprevalence between developed and developing regions. In the less developed regions of Asia and Africa, a high seropositivity rate has been reported for hepatitis E virus (HEV) antibodies. Although acute hepatitis E is often self-limited and has a favorable prognosis, some populations experience severe manifestations, which may progress to liver failure. Moreover, some immunocompromised patients are at risk of developing chronic HEV infection and cirrhosis. Proactive screening, reducing misdiagnosis, improving patient management, timely antiviral therapy for severe and chronic cases, and vaccination of high-risk groups are important measures to reduce the morbidity of hepatitis E. This review focused on the clinical presentation, management, and prevention of hepatitis E.

Keywords

Hepatitis E / Chronic hepatitis / Screening / Antiviral therapy / Vaccination

Cite this article

Download citation ▾

Qiumin Luo, Jia Chen, Yeqiong Zhang, Wenxiong Xu, Ying Liu, Chan Xie, Liang Peng. Viral hepatitis E: Clinical manifestations, treatment, and prevention^☆. Liver Research, 2024, 8(1): 11-21 DOI:10.1016/j.livres.2024.01.001

登录浏览全文

4963

注册一个新账户忘记密码

Authors' contributions

Qiumin Luo and Jia Chen contributed equally to this work and should be considered co-ﬁrst authors. Qiumin Luo: Writing -original draft, Writing - review & editing. Jia Chen: Writing -original draft. Yeqiong Zhang: Writing - review & editing. Wen-xiong Xu: Supervision, Writing - review & editing. Ying Liu: Conceptualization, Writing - review & editing. Chan Xie: Project administration. Liang Peng: Conceptualization, Funding acquisi-tion. All authors have read and agreed to the published version of the manuscript.

Declaration of competing interest

The authors declare that they have no conflict of interest.

Acknowledgments

This work was supported by grants from the Natural Science Foundation of China (No.82070611), Natural Science Foundation of Guangdong Province (2020A1515010317), Guangdong Basic and Applied Basic Research Foundation (No. 21202104030000608 and 2021A1515220029), Guangzhou Science and Technology Plan Pro-jects (No. 202102010204 and 2023B03J1287), Guangzhou Science and Technology Program Key Projects (No. 2023B01J1007), Sun Yat-sen University Clinical Research 5010 Program (No. 2020007 and 2018009), Transformation of Scientiﬁc and Technological Achieve-ments Project of Sun Yat-sen University (No. 82000-18843236), and the Five-Year Plan of the Third Afﬁliated Hospital of Sun Yat-sen University (No.K00006 and P02421).

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Wong DC, Purcell RH, Sreenivasan MA, Prasad SR, Pavri KM. Epidemic and endemic hepatitis in India: evidence for a non-A, non-B hepatitis virus aetiology. Lancet. 1980;2:876-879. https://doi.org/10.1016/s0140-6736(80)92045-0.

[2]	Khuroo MS. Study of an epidemic of non-A, non-B hepatitis. Possibility of another human hepatitis virus distinct from post-transfusion non-A, non-B type. Am J Med. 1980;68:818-824. https://doi.org/10.1016/0002-9343(80)90200-4.

[3]	Balayan MS, Andjaparidze AG, Savinskaya SS, et al. Evidence for a virus in non-A, non-B hepatitis transmitted via the fecal-oral route. Intervirology. 1983;20: 23-31. https://doi.org/10.1159/000149370.

[4]	Reyes GR, Purdy MA, Kim JP, et al. Isolation of a cDNA from the virus responsible for enterically transmitted non-A, non-B hepatitis. Science. 1990;247:1335-1339. https://doi.org/10.1126/science.2107574.

[5]	Kamar N, Izopet J, Tripon S, et al. Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med. 2014;370:1111-1120. https://doi.org/10.1056/NEJMoa1215246.

[6]	Halac U, Beland K, Lapierre P, et al. Cirrhosis due to chronic hepatitis E infection in a child post-bone marrow transplant. J Pediatr. 2012;160: 871-874.e1. https://doi.org/10.1016/j.jpeds.2012.01.028.

[7]	Leoni S, Casabianca A, Biagioni B, Serio I. Viral hepatitis: innovations and expectations. World J Gastroenterol. 2022;28:517-531. https://doi.org/10.3748/wjg.v28.i5.517.

[8]	Hamid SS, Atiq M, Shehzad F, et al. Hepatitis E virus superinfection in patients with chronic liver disease. Hepatology. 2002;36:474-478. https://doi.org/10.1053/jhep.2002.34856.

[9]	Chinese Society of Hepatology. Chinese Medical Association.Consensus on prevention and treatment of hepatitis E. Zhonghua Gan Zang Bing Za Zhi. 2022;30:820-831. https://doi.org/10.3760/cma.j.cn501113-20220729-00401.

[10]	Tarantino P, Viale G, Press MF, et al. ESMO expert consensus statements (ECS) on the deﬁnition, diagnosis, and management of HER2-low breast cancer. Ann Oncol. 2023;34:645-659. https://doi.org/10.1016/j.annonc.2023.05.008.

[11]	Ankcorn MJ, Ijaz S, Poh J, et al. Toward systematic screening for persistent hepatitis E virus infections in transplant patients. Transplantation. 2018;102: 1139-1147. https://doi.org/10.1097/TP.0000000000002097.

[12]	World Health Organization (WHO). Hepatitis E. https://www.who.int/zh/news-room/fact-sheets/detail/hepatitis-e. Accessed October 9, 2023.

[13]	Lu L, Li C, Hagedorn CH. Phylogenetic analysis of global hepatitis E virus se-quences: genetic diversity, subtypes and zoonosis. Rev Med Virol. 2006;16: 5-36. https://doi.org/10.1002/rmv.482.

[14]	Tesse S, Lioure B, Fornecker L, et al. Circulation of genotype 4 hepatitis E virus in Europe: ﬁrst autochthonous hepatitis E infection in France. J Clin Virol. 2012;54:197-200. https://doi.org/10.1016/j.jcv.2012.02.007.

[15]	Liu P, Li L, Wang L, et al. Phylogenetic analysis of 626 hepatitis E virus (HEV) isolates from humans and animals in China (1986-2011) showing genotype diversity and zoonotic transmission. Infect Genet Evol. 2012;12:428-434. https://doi.org/10.1016/j.meegid.2012.01.017.

[16]	Kamar N, Izopet J, Pavio N, et al. Hepatitis E virus infection. Nat Rev Dis Prim. 2017;3:17086. https://doi.org/10.1038/nrdp.2017.86.

[17]	Ditah I, Ditah F, Devaki P, Ditah C, Kamath PS, Charlton M. Current epidemi-ology of hepatitis E virus infection in the United States: low seroprevalence in the national health and nutrition evaluation survey. Hepatology. 2014;60: 815-822. https://doi.org/10.1002/hep.27219.

[18]	Fix AD, Abdel-Hamid M, Purcell RH, et al. Prevalence of antibodies to hepatitis E in two rural Egyptian communities. Am J Trop Med Hyg. 2000;62:519-523. https://doi.org/10.4269/ajtmh.2000.62.519.

[19]	Kmush B, Wierzba T, Krain L, Nelson K, Labrique AB. Epidemiology of hepatitis E in low- and middle-income countries of Asia and Africa. Semin Liver Dis. 2013;33:15-29. https://doi.org/10.1055/s-0033-1338111.

[20]	Stoszek SK, Abdel-Hamid M, Saleh DA, et al. High prevalence of hepatitis E antibodies in pregnant Egyptian women. Trans R Soc Trop Med Hyg. 2006;100: 95-101. https://doi.org/10.1016/j.trstmh.2004.12.005.

[21]	Li W, Shu X, Pu Y, Bi J, Yang G, Yin G. Seroprevalence and molecular detection of hepatitis E virus in Yunnan Province, China. Arch Virol. 2011;156: 1989-1995. https://doi.org/10.1007/s00705-011-1089-6.

[22]	Dong C, Dai X, Shao JS, Hu K, Meng JH. Identiﬁcation of genetic diversity of hepatitis E virus (HEV) and determination of the seroprevalence of HEV in eastern China. Arch Virol. 2007;152:739-746. https://doi.org/10.1007/s00705-006-0882-0.

[23]	Li RC, Ge SX, Li YP, et al. Seroprevalence of hepatitis E virus infection, rural southern People’s Republic of China. Emerg Infect Dis. 2006;12:1682-1688. https://doi.org/10.3201/eid1211.060332.

[24]	National Health Commission of the People’s Republic of China. Epidemic Sit-uation of Notiﬁable Infectious Diseases in China; 2022 [EB/OL] http://www.nhc. gov.cn/. Accessed October 9, 2023

[25]	Velavan TP, Pallerla SR, Johne R, et al. Hepatitis E: an update on one health and clinical medicine. Liver Int. 2021;41:1462-1473. https://doi.org/10.1111/liv.14912.

[26]

El-Sayed Zaki M, El-Deen Zaghloul MH, El Sayed O. Acute sporadic hepatitis E in children: diagnostic relevance of speciﬁc immunoglobulin M and immu-noglobulin G compared with nested reverse transcriptase PCR. FEMS Immunol Med Microbiol. 2006;48:16-20. https://doi.org/10.1111/j.1574-695X.2006.00111.x.

[27]	Rein DB, Stevens GA, Theaker J, Wittenborn JS, Wiersma ST. The global burden of hepatitis E virus genotypes 1 and 2 in 2005. Hepatology. 2012; 55:988-997. https://doi.org/10.1002/hep.25505.

[28]	Wedemeyer H, Pischke S, Manns MP. Pathogenesis and treatment of hepatitis E virus infection. Gastroenterology. 2012;142:1388-1397.e1. https://doi.org/10.1053/j.gastro.2012.02.014.

[29]	Yamazaki Y, Naganuma A, Arai Y, et al. Clinical and virological features of acute hepatitis E in Gunma prefecture, Japan between 2004 and 2015. Hepatol Res. 2017; 47:435-445. https://doi.org/10.1111/hepr.12765.

[30]	Legrand-Abravanel F, Kamar N, Sandres-Saune K, et al. Characteristics of autochthonous hepatitis E virus infection in solid-organ transplant recipients in France. J Infect Dis. 2010;202:835-844. https://doi.org/10.1086/655899.

[31]	Aggarwal R, Goel A. Natural history, clinical manifestations, and pathogenesis of hepatitis E virus genotype 1 and 2 infections. Cold Spring Harb Perspect Med. 2019;9:a032136. https://doi.org/10.1101/cshperspect.a032136.

[32]	Wallace SJ, Swann R, Donnelly M, et al. Mortality and morbidity of locally acquired hepatitis E in the national Scottish cohort: a multicentre retro-spective study. Aliment Pharmacol Ther. 2020;51:974-986. https://doi.org/10.1111/apt.15704.

[33]	Wang Y, Liu H, Liu S, et al. Incidence, predictors and prognosis of genotype 4 hepatitis E related liver failure: a tertiary nested case-control study. Liver Int. 2019;39:2291-2300. https://doi.org/10.1111/liv.14221.

[34]	Shalimar Kedia S, Gunjan D, et al. Acute liver failure due to hepatitis E virus infection is associated with better survival than other etiologies in Indian patients. Dig Dis Sci. 2017;62:1058-1066. https://doi.org/10.1007/s10620-017-4461-x.

[35]	Fang L, Zhang J, Chen H, Lv F, Yu Y, Du X. Epidemiological characteristics and clinical manifestations of hepatitis E in a tertiary hospital in China: a retro-spective study. Front Microbiol. 2022;12:831968. https://doi.org/10.3389/fmicb.2021.831968.

[36]	Drebber U, Odenthal M, Aberle SW, et al. Hepatitis E in liver biopsies from patients with acute hepatitis of clinically unexplained origin. Front Physiol. 2013;4:351. https://doi.org/10.3389/fphys.2013.00351.

[37]	Wu J, Guo Y, Lu X, et al. Th1/Th 2 cells and associated cytokines in acute hepatitis e and related acute liver failure. J Immunol Res. 2020;2020:6027361. https://doi.org/10.1155/2020/6027361.

[38]	Murata K, Kang JH, Nagashima S, et al. IFN-l 3 as a host immune response in acute hepatitis E virus infection. Cytokine. 2020;125:154816. https://doi.org/10.1016/j.cyto.2019.154816.

[39]	European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017; 67:370-398. https://doi.org/10.1016/j.jhep.2017.03.021.

[40]	Kamar N, Garrouste C, Haagsma EB, et al. Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology. 2011; 140:1481-1489. https://doi.org/10.1053/j.gastro.2011.02.050.

[41]	Lampejo T, Curtis C, Ijaz S, et al. Nosocomial transmission of hepatitis E virus and development of chronic infection: the wider impact of COVID-19. J Clin Virol. 2022;148:105083. https://doi.org/10.1016/j.jcv.2022.105083.

[42]	van Bijnen ST, Ledeboer M, Martens HA. Chronic hepatitis E in a patient with rheumatoid arthritis treated with adalimumab and methotrexate. Rheumatology (Oxford). 2017;56:497-498. https://doi.org/10.1093/rheuma-tology/kew388.

[43]	Neukam K, Barreiro P, Macías J, et al. Chronic hepatitis E in HIV patients: rapid progression to cirrhosis and response to oral ribavirin. Clin Infect Dis. 2013;57: 465-468. https://doi.org/10.1093/cid/cit224.

[44]	Kamar N, Weclawiak H, Guilbeau-Frugier C, et al. Hepatitis E virus and the kidney in solid-organ transplant patients. Transplantation. 2012;93:617-623. https://doi.org/10.1097/TP.0b013e318245f14c.

[45]	Ma Z, de Man RA, Kamar N, Pan Q. Chronic hepatitis E: advancing research and patient care. J Hepatol. 2022;77:1109-1123. https://doi.org/10.1016/j.jhep.2022.05.006.

[46]	Wang Y, Liu S, Pan Q, Zhao J. Chronic hepatitis E in an immunocompetent patient. Clin Res Hepatol Gastroenterol. 2020;44:e66ee68. https://doi.org/10.1016/j.clinre.2019.08.001.

[47]	Liu L, Liu Y, Du Y, et al. Analysis of long-term follow-up and examination of pathological liver tissue in chronic hepatitis E. Dig Liver Dis. 2016;48: 684-686. https://doi.org/10.1016/j.dld.2016.02.016.

[48]	Suneetha PV, Pischke S, Schlaphoff V, et al. Hepatitis E virus (HEV)-speciﬁcT-cell responses are associated with control of HEV infection. Hepatology. 2012;55:695-708. https://doi.org/10.1002/hep.24738.

[49]	Rogers E, Todd SM, Pierson FW, et al. CD8þlymphocytes but not B lympho-cytes are required for protection against chronic hepatitis E virus infection in chickens. J Med Virol. 2019;91:1960-1969. https://doi.org/10.1002/jmv.25548.

[50]	Kemming J, Gundlach S, Panning M, et al. Mechanisms of CD8þ T-cell failure in chronic hepatitis E virus infection. J Hepatol. 2022;77:978-990. https://doi.org/10.1016/j.jhep.2022.05.019.

[51]	Moal V, Textoris J, Ben Amara A, et al. Chronic hepatitis E virus infection is speciﬁcally associated with an interferon-related transcriptional program. J Infect Dis. 2013;207:125-132. https://doi.org/10.1093/infdis/jis632.

[52]	Boccia D, Guthmann JP, Klovstad H, et al. High mortality associated with an outbreak of hepatitis E among displaced persons in Darfur, Sudan. Clin Infect Dis. 2006;42:1679-1684. https://doi.org/10.1086/504322.

[53]	Hussaini SH, Skidmore SJ, Richardson P, Sherratt LM, Cooper BT, O’Grady JG. Severe hepatitis E infection during pregnancy. J Viral Hepat. 1997;4:51-54. https://doi.org/10.1046/j.1365-2893.1997.00123.x.

[54]	Perez-Gracia MT, Suay-García B, Mateos-Lindemann ML. Hepatitis E and pregnancy: current state. Rev Med Virol. 2017;27:e1929. https://doi.org/10.1002/rmv.1929.

[55]	Kumar RM, Uduman S, Rana S, Kochiyil JK, Usmani A, Thomas L. Sero-prev-alence and mother-to-infant transmission of hepatitis E virus among preg-nant women in the United Arab Emirates. Eur J Obstet Gynecol Reprod Biol. 2001;100:9-15. https://doi.org/10.1016/s0301-2115(01)00448-1.

[56]	Qian Z, Li T, Zhang Y, et al. Prevalence of hepatitis E virus and its association with adverse pregnancy outcomes in pregnant women in China. J Clin Virol. 2023;158:105353. https://doi.org/10.1016/j.jcv.2022.105353.

[57]	Zhang F, Wang J, Cheng J, et al. Clinical features of sporadic hepatitis E virus infection in pregnant women in Shanghai, China. J Infect. 2022;84:64-70. https://doi.org/10.1016/j.jinf.2021.11.004.

[58]	Qian Z, Li T, Xia Y, et al. Genotype 4 Hepatitis E virus replicates in the placenta, causes severe histopathological damage, and vertically transmits to fetuses. J Infect. 2023;87:34-45. https://doi.org/10.1016/j.jinf.2023.05.003.

[59]	Yu W, Hao X, Li Y, et al. Vertical transmission of hepatitis E virus in pregnant rhesus macaques. Sci Rep. 2020;10:17517. https://doi.org/10.1038/s41598-020-74461-7.

[60]	Gouilly J, Chen Q, Siewiera J, et al. Genotype speciﬁc pathogenicity of hepatitis E virus at the human maternal-fetal interface. Nat Commun. 2018;9:4748. https://doi.org/10.1038/s41467-018-07200-2.

[61]	Wu Y, Tan HWS, Lin J-Y, Shen H-M, Wang H, Lu G. Molecular mechanisms of autophagy and implications in liver diseases. Liver Res. 2023;7:56-70. https://doi.org/10.1016/j.livres.2023.02.002.

[62]	Yang Y, Liu B, Tian J, Teng X, Liu T. Vital role of autophagy flux inhibition of placental trophoblast cells in pregnancy disorders induced by HEV infection. Emerg Microb Infect. 2023;12:2276336. https://doi.org/10.1080/22221751.2023.2276336.

[63]	Qiu LX, Huang Y, Quan JL, et al. Prognosis of hepatitis E infection in patients with chronic liver disease: a meta-analysis. J Viral Hepat. 2023;30:101-107. https://doi.org/10.1111/jvh.13754.

[64]	Zhao H, Ye W, Yu X, et al. Hepatitis E virus superinfection impairs long-term outcome in hospitalized patients with hepatitis B virus-related decom-pensated liver cirrhosis. Ann Hepatol. 2023;28:100878. https://doi.org/10.1016/j.aohep.2022.100878.

[65]	Tseng TC, Liu CJ, Chang CT, et al. HEV superinfection accelerates disease progression in patients with chronic HBV infection and increases mortality in those with cirrhosis. J Hepatol. 2020;72:1105-1111. https://doi.org/10.1016/j.jhep.2020.01.012.

[66]	El Sayed Zaki M, Othman W. Role of hepatitis E infection in acute on chronic liver failure in Egyptian patients. Liver Int. 2011;31:1001-1005. https://doi.org/10.1111/j.1478-3231.2011.02521.x.

[67]	Shalimar Kedia S, Mahapatra SJ, et al. Severity and outcome of acute-on-chronic liver failure is dependent on the etiology of acute hepatic insults: analysis of 368 patients. J Clin Gastroenterol. 2017;51:734-741. https://doi.org/10.1097/MCG.0000000000000823.

[68]	Wang Y, Liu H, Jiang Y, Pan Q, Zhao J. Poor outcomes of acute hepatitis E in patients with cirrhotic liver diseases regardless of etiology. Open Forum Infect Dis. 2020;7:ofaa107. https://doi.org/10.1093/oﬁd/ofaa107.

[69]	Cheng SH, Mai L, Zhu FQ, et al. Influence of chronic HBV infection on super-imposed acute hepatitis E. World J Gastroenterol. 2013;19:5904-5909. https://doi.org/10.3748/wjg.v19.i35.5904.

[70]	Abravanel F, Pique J, Couturier E, et al. Acute hepatitis E in French patients and neurological manifestations. J Infect. 2018;77:220-226. https://doi.org/10.1016/j.jinf.2018.06.007.

[71]	Ripellino P, Pasi E, Melli G, et al. Neurologic complications of acute hepatitis E virus infection. Neurol Neuroimmunol Neuroinflamm. 2019;7:e643. https://doi.org/10.1212/NXI.0000000000000643.

[72]	Jha AK, Kumar G, Dayal VM, Ranjan A, Suchismita A. Neurological manifes-tations of hepatitis E virus infection: an overview. World J Gastroenterol. 2021;27:2090-2104. https://doi.org/10.3748/wjg.v27.i18.2090.

[73]	Woolson KL, Forbes A, Vine L, et al. Extra-hepatic manifestations of autoch-thonous hepatitis E infection. Aliment Pharmacol Ther. 2014;40:1282-1291. https://doi.org/10.1111/apt.12986.

[74]	Bazerbachi F, Haffar S, Garg SK, Lake JR. Extra-hepatic manifestations asso-ciated with hepatitis E virus infection: a comprehensive review of the liter-ature. Gastroenterol Rep (Oxf). 2016;4:1-15. https://doi.org/10.1093/gastro/gov042.

[75]	Abravanel F, Nicot F, Lhomme S, et al. Hepatitis E virus quasispecies in cere-brospinal fluid with neurological manifestations. Vaccines(Basel). 2021;9: 1205. https://doi.org/10.3390/vaccines9101205.

[76]	Fritz M, Berger B, Schemmerer M, et al. Pathological cerebrospinal fluid ﬁndings in patients with neuralgic amyotrophy and acute hepatitis E virus infection. J Infect Dis. 2018;217:1897-1901. https://doi.org/10.1093/infdis/jiy128.

[77]	Drave SA, Debing Y, Walter S, et al. Extra-hepatic replication and infection of hepatitis E virus in neuronal-derived cells. J Viral Hepat. 2016;23:512-521. https://doi.org/10.1111/jvh.12515.

[78]	Tian D, Li W, Heffron CL, et al. Hepatitis E virus infects brain microvascular endothelial cells, crosses the blood-brain barrier, and invades the central nervous system. Proc Natl Acad Sci U S A. 2022;119:e2201862119. https://doi.org/10.1073/pnas.2201862119.

[79]	Zhou X, Huang F, Xu L, et al. Hepatitis E virus infects neurons and brains. J Infect Dis. 2017;215:1197-1206. https://doi.org/10.1093/infdis/jix079.

[80]	Brehm TT, Mazaheri O, Horvatits T, et al. Lower levels of transaminases but higher levels of serum creatinine in patients with acute hepatitis E in com-parison to patients with hepatitis A. Pathogens. 2021;10:60. https://doi.org/10.3390/pathogens10010060.

[81]	Perrin HB, Cintas P, Abravanel F, et al. Neurologic disorders in immunocom-petent patients with autochthonous acute hepatitis E. Emerg Infect Dis. 2015;21:1928-1934. https://doi.org/10.3201/eid2111.141789.

[82]	El-Mokhtar MA, Kamel AM, El-Sabaa EMW, et al. Evidence of a link between hepatitis E virus exposure and glomerulonephritis development. Viruses. 2023;15:1379. https://doi.org/10.3390/v15061379.

[83]	Guinault D, Ribes D, Delas A, et al. Hepatitis E virus-induced cryoglobulinemic glomerulonephritis in a nonimmunocompromised person. Am J Kidney Dis. 2016;67:660-663. https://doi.org/10.1053/j.ajkd.2015.10.022.

[84]	Pischke S, Behrendt P, Manns MP, Wedemeyer H. HEV-associated cry-oglobulinaemia and extrahepatic manifestations of hepatitis E. Lancet Infect Dis. 2014;14:678-679. https://doi.org/10.1016/S1473-309970823-0.

[85]	Marion O, Abravanel F, Del Bello A, et al. Hepatitis E virus-associated cry-oglobulinemia in solid-organ-transplant recipients. Liver Int. 2018;38: 2178-2189. https://doi.org/10.1111/liv.13894.

[86]	Wu J, Xiang Z, Zhu C, et al. Extrahepatic manifestations related to hepatitis E virus infection and their triggering mechanisms. J Infect. 2021;83:298-305. https://doi.org/10.1016/j.jinf.2021.07.021.

[87]	Sayed IM, Seddik MI, Gaber MA, Saber SH, Mandour SA, El-Mokhtar MA. Replication of hepatitis E virus (HEV) in primary human-derived monocytes and macrophages in vitro. Vaccines(Basel). 2020;8:239. https://doi.org/10.3390/vaccines8020239.

[88]	Wang L, Yan L, Jiang J, et al. Presence and persistence of hepatitis E virus RNA and proteins in human bone marrow. Emerg Microb Infect. 2020;9:994-997. https://doi.org/10.1080/22221751.2020.1761762.

[89]

Chinese Society of Infectious Diseases. Expert Consensus Committee on Liver Inflammation and its Prevention and Treatment. Consensus statement by the expert committee for prevention and management of liver inflammation in China. Chin J Hepatol. 2014;22:94-103. https://doi.org/10.3760/CMA.-J.ISSN.1007-3418.2014.02.006.

[90]	Kar P, Sengupta A. A guide to the management of hepatitis E infection during pregnancy. Expet Rev Gastroenterol Hepatol. 2019;13:205-211. https://doi.org/10.1080/17474124.2019.1568869.

[91]	Peron JM, Dalton H, Izopet J, Kamar N. Acute autochthonous hepatitis E in western patients with underlying chronic liver disease: a role for ribavirin? J Hepatol. 2011;54:1323-1325. https://doi.org/10.1016/j.jhep.2011.01.009.

[92]	Manka P, Bechmann LP, Coombes JD, et al. Hepatitis E Virus infection as a possible cause of acute liver failure in Europe. Clin Gastroenterol Hepatol. 2015;13:1836ee158. https://doi.org/10.1016/j.cgh.2015.04.014.

[93]	Gorris M, van der Lecq BM, van Erpecum KJ, Treatment for chronic hepatitis E virus infection: a systematic review and meta-analysis. J Viral Hepat. 2021;28:454-463. https://doi.org/10.1111/jvh.13456.

[94]	Kamar N, Izopet J, Tripon S, et al. Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med. 2014;370:1111-1120. https://doi.org/10.1056/NEJMoa1215246.

[95]	Kamar N, Abravanel F, Behrendt P, et al. Ribavirin for hepatitis E virus infection after organ transplantation: a large European retrospective multicenter study. Clin Infect Dis. 2020;71:1204-1211. https://doi.org/10.1093/cid/ciz953.

[96]	Marion O, Lhomme S, Del Bello A, et al. Monitoring hepatitis E virus fecal shedding to optimize ribavirin treatment duration in chronically infected transplant patients. J Hepatol. 2019;70:206-209. https://doi.org/10.1016/j.jhep.2018.09.011.

[97]	Debing Y, Ramiere C, Dallmeier K, et al. Hepatitis E virus mutations associated with ribavirin treatment failure result in altered viral ﬁtness and ribavirin sensitivity. J Hepatol. 2016;65:499-508. https://doi.org/10.1016/j.jhep.2016.05.002.

[98]	Todt D, Gisa A, Radonic A, et al. In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome. Gut. 2016;65:1733-1743. https://doi.org/10.1136/gutjnl-2015-311000.

[99]	Wang B, Mahsoub HM, Li W, et al. Ribavirin treatment failure-associated mutation, Y1320H, in the RNA-dependent RNA polymerase of genotype 3 hepatitis E virus (HEV) enhances virus replication in a rabbit HEV infection model. mBio. 2023;14:e0337222. https://doi.org/10.1128/mbio.03372-22.

[100]

Kamar N, Rostaing L, Abravanel F, et al. Pegylated interferon-alpha for treating chronic hepatitis E virus infection after liver transplantation. Clin Infect Dis. 2010;50:e30ee33. https://doi.org/10.1086/650488.

[101]

Haagsma EB, Riezebos-Brilman A, van den Berg AP, Porte RJ, Niesters HG.Treatment of chronic hepatitis E in liver transplant recipients with pegylated interferon alpha-2b. Liver Transpl. 2010; 16:474-477. https://doi.org/10.1002/lt.22014.

[102]

Dao Thi VL, Debing Y, Wu X, et al. Sofosbuvir inhibits hepatitis E virus replication in vitro and results in an additive effect when combined with ribavirin. Gastroenterology. 2016;150:82-85.e4. https://doi.org/10.1053/j.gastro.2015.09.011.

[103]

Liang Z, Shu J, He Q, et al. High dose sofosbuvir and sofosbuvir-plus-ribavirin therapy inhibit hepatitis E virus (HEV) replication in a rabbit model for acute HEV infection. Antivir Res. 2022;199:105274. https://doi.org/10.1016/j.antiviral.2022.105274.

[104]

Biliotti E, Franchi C, Spaziante M, et al. Autochthonous acute hepatitis E: treatment with sofosbuvir and ribavirin. Infection. 2018;46:725-727. https://doi.org/10.1007/s15010-018-1168-7.

[105]

Cornberg M, Pischke S, Müller T, et al. Sofosbuvir monotherapy fails to achieve HEV RNA elimination in patients with chronic hepatitis E - the HepNet SofE pilot study. J Hepatol. 2020;73:696-699. https://doi.org/10.1016/j.jhep.2020.05.020.

[106]

Gallacher J, Taha Y, da Silva Filipe A, Ijaz S, McPherson S. ledipasvir/sofosbuvir and ribavirin for the treatment of ribavirin-refractory persistent hepatitis E virus infection. IDCases. 2023;32:e01741. https://doi.org/10.1016/j.idcr.2023.e01741.

[107]

Todt D, Moeller N, Praditya D, et al. The natural compound silvestrol inhibits hepatitis E virus (HEV) replication in vitro and in vivo. Antivir Res. 2018;157: 151-158. https://doi.org/10.1016/j.antiviral.2018.07.010.

[108]

Miao Z, Zhang R, Yu P, Li Y, Pan Q, Li Y. The macrolide antibiotic azithromycin potently inhibits hepatitis E virus in cell culture models. Int J Antimicrob Agents. 2021;58:106383. https://doi.org/10.1016/j.ijantimicag.2021.106383.

[109]

Zhang F, Xu LD, Zhang Q, et al. Targeting proteostasis of the HEV replicase to combat infection in preclinical models. J Hepatol. 2023;78:704-716. https://doi.org/10.1016/j.jhep.2022.12.010.

[110]

Primadharsini PP, Nagashima S, Takahashi M, Murata K, Okamoto H. Rito-navir blocks hepatitis E virus internalization and clears hepatitis E virus in vitro with ribavirin. Viruses. 2022;14:2440. https://doi.org/10.3390/v14112440.

[111]

Soon CF, Behrendt P, Todt D, et al. Deﬁning virus-speciﬁc CD8þ TCR reper-toires for therapeutic regeneration of T cells against chronic hepatitis E. J Hepatol. 2019;71:673-684. https://doi.org/10.1016/j.jhep.2019.06.005.

[112]

Zhang C, Freistaedter A, Schmelas C, Gunkel M, Dao Thi VL, Grimm D. An RNA interference/adeno-associated virus vector-based combinatorial gene therapy approach against hepatitis E virus. Hepatol Commun. 2022;6:878-888. https://doi.org/10.1002/hep4.1842.

[113]

Neumann-Haefelin C. Paving the way for T cell-based immunotherapies in chronic hepatitis E. J Hepatol. 2019;71:648-650. https://doi.org/10.1016/j.jhep.2019.07.018.

[114]

Donnelly MC, Imlach SN, Abravanel F, et al. Sofosbuvir and daclatasvir anti-viral therapy fails to clear HEV viremia and restore reactive T cells in a HEV/HCV co-infected liver transplant recipient. Gastroenterology. 2017;152: 300-301. https://doi.org/10.1053/j.gastro.2016.05.060.

[115]

Sari G, Mulders CE, Zhu J, et al. Treatment induced clearance of hepatitis E viruses by interferon-lambda in liver-humanized mice. Liver Int. 2021;41: 2866-2873. https://doi.org/10.1111/liv.15033.

[116]

Li P, Li Y, Wang Y, et al. Recapitulating hepatitis E virus-host interactions and facilitating antiviral drug discovery in human liver-derived organoids. Sci Adv. 2022;8:eabj5908. https://doi.org/10.1126/sciadv.abj5908.

[117]

Wang Y, Zhou X, Debing Y, et al. Calcineurin inhibitors stimulate and myco-phenolic acid inhibits replication of hepatitis E virus. Gastroenterology. 2014;146:1775-1783. https://doi.org/10.1053/j.gastro.2014.02.036.

[118]

Wang Y, Wang W, Xu L, et al. Cross talk between nucleotide synthesis pathways with cellular immunity in constraining hepatitis E virus replication. Antimicrob Agents Chemother. 2016;60:2834-2848. https://doi.org/10.1128/AAC.02700-15.

[119]

Debing Y, Emerson SU, Wang Y, et al. Ribavirin inhibits in vitro hepatitis E virus replication through depletion of cellular GTP pools and is moderately synergistic with alpha interferon. Antimicrob Agents Chemother. 2014;58: 267-273. https://doi.org/10.1128/AAC.01795-13.

[120]

Li Y, Li P, Li Y, et al. Drug screening identiﬁed gemcitabine inhibiting hepatitis E virus by inducing interferon-like response via activation of STAT1 phos-phorylation. Antivir Res. 2020;184:104967. https://doi.org/10.1016/j.antiviral.2020.104967.

[121]

Glitscher M, Himmelsbach K, Woytinek K, et al. Inhibition of hepatitis E virus spread by the natural compound silvestrol. Viruses. 2018;10:301. https://doi.org/10.3390/v10060301.

[122]

Primadharsini PP, Nagashima S, Nishiyama T, Takahashi M, Murata K, Okamoto H. Development of recombinant infectious hepatitis E virus harboring the nanoKAZ gene and its application in drug screening. J Virol. 2022;96:e0190621. https://doi.org/10.1128/jvi.01906-21.

[123]

Nimgaonkar I, Archer NF, Becher I, et al. Isocotoin suppresses hepatitis E virus replication through inhibition of heat shock protein 90. Antivir Res. 2021;185: 104997. https://doi.org/10.1016/j.antiviral.2020.104997.

[124]

Gupta J, Irfan M, Ramgir N, et al. Antiviral activity of zinc oxide nanoparticles and tetrapods against the hepatitis E and hepatitis C viruses. Front Microbiol. 2022;13:881595. https://doi.org/10.3389/fmicb.2022.881595.

[125]

Kaushik N, Subramani C, Anang S, et al. Zinc salts block hepatitis E virus replication by inhibiting the activity of viral RNA-dependent RNA polymerase. J Virol. 2017; 91:e00754-17. https://doi.org/10.1128/JVI.00754-17.

[126]

Gu Y, Tang X, Zhang X, et al. Structural basis for the neutralization of hepatitis E virus by a cross-genotype antibody. Cell Res. 2015;25:604-620. https://doi.org/10.1038/cr.2015.34.

[127]

Desai AN. Hepatitis E. JAMA. 2020;323:1862. https://doi.org/10.1001/jama.2019.21495.

[128]

Geng Y, Zhao C, Huang W, et al. Detection and assessment of infectivity of hepatitis E virus in urine. J Hepatol. 2016;64:37-43. https://doi.org/10.1016/j.jhep.2015.08.034.

[129]

Guillois Y, Abravanel F, Miura T, et al. High proportion of asymptomatic infections in an outbreak of hepatitis E associated with a spit-roasted piglet, France, 2013. Clin Infect Dis. 2016; 62:351-357. https://doi.org/10.1093/cid/civ862.

[130]

Chironna M, Germinario C, Lopalco PL, Carrozzini F, Barbuti S, Quarto M. Prevalence rates of viral hepatitis infections in refugee Kurds from Iraq and Turkey. Infection. 2003;31:70-74. https://doi.org/10.1007/s15010-002-3100-3.

[131]

Browne LB, Menkir Z, Kahi V, et al. Notes from the ﬁeld: hepatitis E outbreak among refugees from South Sudan - gambella, Ethiopia, April 2014-January 2015. MMWR Morb Mortal Wkly Rep. 2015;64:537.

[132]

Matsubayashi K, Kang JH, Sakata H, et al. A case of transfusion-transmitted hepatitis E caused by blood from a donor infected with hepatitis E virus via zoonotic food-borne route. Transfusion. 2008;48:1368-1375. https://doi.org/10.1111/j.1537-2995.2008.01722.x.

[133]

Haïm-Boukobza S, Ferey MP, Vetillard AL, et al. Transfusion-transmitted hepatitis E in a misleading context of autoimmunity and drug-induced toxicity. JHepatol. 2012;57:1374-1378. https://doi.org/10.1016/j.jhep.2012.08.001.

[134]

Boxall E, Herborn A, Kochethu G, et al. Transfusion-transmitted hepatitis E in a “nonhyperendemic” country. Transfus Med. 2006;16:79-83. https://doi.org/10.1111/j.1365-3148.2006.00652.x.

[135]

Wang M, Fu P, Yin Y, He M, Liu Y. Acute, recent and past HEV infection among voluntary blood donors in China: a systematic review and meta-analysis. PLoS One. 2016;11:e0161089. https://doi.org/10.1371/journal.pone.0161089.

[136]

Gallian P, Lhomme S, Piquet Y, et al. Hepatitis E virus infections in blood donors, France. Emerg Infect Dis. 2014;20:1914-1917. https://doi.org/10.3201/eid2011.140516.

[137]

Bi H, Yang R, Wu C, Xia J. Hepatitis E virus and blood transfusion safety. Epidemiol Infect. 2020;148:e158. https://doi.org/10.1017/S0950268820001429.

[138]

Fantilli A, Lopez Villa SD, Zerega A, et al. Hepatitis E virus infection in a patient with alcohol related chronic liver disease: a case report of acute-on-chronic liver failure. Virol J. 2021;18:245. https://doi.org/10.1186/s12985-021-01714-w.

[139]

Patra S, Kumar A, Trivedi SS, Puri M, Sarin SK. Maternal and fetal outcomes in pregnant women with acute hepatitis E virus infection. Ann Intern Med. 2007;147:28-33. https://doi.org/10.7326/0003-4819-147-1-200707030-00005.

[140]

Zhu FC, Zhang J, Zhang XF, et al. Efﬁcacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet. 2010;376:895-902. https://doi.org/10.1016/S0140-673661030-6.

[141]

Zhang J, Zhang XF, Huang SJ, et al. Long-term efﬁcacy of a hepatitis E vaccine. N Engl J Med. 2015;372:914-922. https://doi.org/10.1056/NEJMoa1406011.

[142]

Yu XY, Chen ZP, Wang SY, et al. Safety and immunogenicity of hepatitis E vaccine in elderly people older than 65 years. Vaccine. 2019;37:4581-4586. https://doi.org/10.1016/j.vaccine.2019.04.006.

[143]

Wu T, Huang SJ, Zhu FC, et al. Immunogenicity and safety of hepatitis E vaccine in healthy hepatitis B surface antigen positive adults. Hum Vaccin Immunother. 2013;9:2474-2479. https://doi.org/10.4161/hv.25814.

[144]

Zhong G, Zhuang C, Hu X, et al. Safety of hepatitis E vaccination for pregnancy: a post-hoc analysis of a randomized, double-blind, controlled phase 3 clinical trial. Emerg Microb Infect. 2023;12:2185456. https://doi.org/10.1080/22221751.2023.2185456.

[145]

Ma JX, Liu YY, Li Q, Ge S, Zhang Z. Study of the prevalence and disease burden of chronic disease in the elderly in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2019;40:451-456. https://doi.org/10.3760/cma.j.issn.0254-6450.2019.04.015.